President, Maria José Alonso
Maria José Alonso, PhD
University of Santiago de Compostela
Professor Department of Pharmacy & Pharmaceutical Technology
CIMUS Research Institute
Maria's lab has pioneered numerous discoveries in the field of Nanopharmaceutical Technology and nanomedicine. She is the author of over 260 scientific contributions with more than 15,300 cites (H factor 69) and the inventor of 20 patent families.
Immediate Past-President, Tamara Minko
Tamara Minko, PhD
Rutgers, The State University of New Jersey
Professor II and Chair of the Department of Pharmaceuticals
Tamara's current research interests include drug delivery; biopharmaceutics; nanotechnology; molecular targeting; antisense oligonucleotides, siRNA and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; macromolecular therapeutics; preclinical evaluation of new therapeutics; modulation of cell death mechanisms during hypoxia.
President-Elect, Justin Hanes
Justin Hanes, PhD
Johns Hopkins University
Lewis J Ort Professor of Ophthalmology
Director for the Center for Nanomedicine
Director of therapeutics for the Institute for NanoBio Technology (INBT)
Justin holds joint appointments in Biomedical Engineering, Chemical & Biomolecular Engineering, Environmental Health Sciences, Neurosurgery, and Oncolog. His degrees are in Chemical Engineering from UCLA (B.S.) and MIT (Ph.D.), and he has completed a postdoctoral fellowship in Oncology and Neurosurgery at Johns Hopkins prior to beginning his faculty position in 1998. .
Secretary, Yvonne Perrie
Yvonne Perrie, PhD
Professor in Drug Delivery
University of Strathclyde, Glasgow, Scotland<,br>
Strathclyde Institute of Pharmacy and Biomedical Sciences
Yvonne gained her PhD from the University of London (1998) investigating the role of liposomes for drug delivery. She then worked developing liposome drug delivery platform technology. Yvonne joined Aston University in 2000 and was appointed Professor in Drug Delivery in 2007. In 2016, Yvonne moved to the University of Strathclyde as part of the Global Talent Appointment Programme. Yvonne’s research is multi-disciplinary and is focused on the development of drug delivery systems to facilitate the delivery of drugs and vaccines.
Treasurer, Samir Mitragotri
Samir Mitragotri, PhD
Professor, John A. Paulson School of Engineering and Applied Sciences
Samir has made groundbreaking contributions to the field of biological barriers and drug delivery.Hei has established a fundamental knowledge-base of transport properties of skin including structure-permeation relationships, pioneered a large number of technologies including low-frequency ultrasound, pulsed microjet injector, high throughput screening (INSIGHT), skin penetrating peptides (SPACE peptide) and ionic liquids (CAGE) for transdermal delivery of proteins, peptides and nucleic acids.
Treasurer-Elect, David Putnam
Professor of Biomedical Engineering & Chemical and Biomolecular Engineering
David received his graduate training at the University of Utah. He was an NIH postdoctoral fellow in the Department of Chemical Engineering at MIT in the laboratory of Professor Robert Langer. He held a joint appointment at MIT and as a Scientific co-Founder of TransForm Pharmaceuticals, Inc., which was acquired by Johnson & Johnson in March, 2005. In 2008-2009 he was an Entrepreneur-in-Residence at PureTech Ventures in Boston, MA where he focused on emerging technologies in the field of drug delivery.
Director-at-Large, Richard Korsmeyer (3-year term through 2019)
Richard Korsmeyer, PhD
Korsmeyer Consulting, LLC
Richard is an internationally-recognized executive leader and scientist providing advice to the pharmaceutical industry. Experienced with specialized drug delivery technology, as well as with generalized chemistry, manufacturing and controls (CMC) for development of pharmaceutical products. He has led, participated in, or supervised hundreds of Due Diligence evaluations for in-licensing, out-licensing, mergers, and acquisitions, including risk assessments and integration strategy. Much of Richard's experience has been related to creating strategies for implementing innovative technologies and product concepts, taking a holistic approach that includes patient needs and corporate objectives, as well as technical considerations and intellectual property.
Director-at-Large, Mark Prausnitz (3-year term through 2019)
Mark Prausnitz, PhD
Georgia Institute of Technology
Regents' Professor, J. Erskine Love Jr. Chair in Chemical & Biomolecular Engineering
Director of the Center for Drug Design, Development and Delivery
Dr. Prausnitz and his colleagues carry out research on biophysical methods of drug delivery, which employ microneedles, ultrasound, lasers, electric fields, heat, convective forces and other physical means to control the transport of drugs, proteins, genes and vaccines into and within the body. His group is advancing microneedles from device design and fabrication through pharmaceutical formulation and preclinical animal studies through studies in human subjects. In addition to developing a self-administered influenza vaccine using microneedles, Dr. Prausnitz is translating microneedles technology especially to make vaccination in developing countries more effective.
Director-at-Large, IlvaRupenthal (3-year term through 2020)
Ilva Rupenthal, PhD
The University of Auckland
Senior Lecturer in the Department of Ophthalmology
Director of the Buchanan Ocular Therapeutics Unit
Ilva received a BPharm from the Philipps-University of Marburg, Germany, in 2003 and completed a PhD on ‘Ocular delivery of antisense oligonucleotides’ with the School of Pharmacy and the Department of Ophthalmology, University of Auckland, in 2008. In 2010, Ilva was awarded a prestigious three-year New Zealand Science and Technology Postdoctoral Fellowship to establish an ocular pharmaceutics group within the New Zealand National Eye Centre. In 2013, she then received a prestigious $500,000 HRC Sir Charles Hercus Research Fellowship to continue her innovative research into stimuli-responsive ocular implants. Dr Rupenthal has received several awards including the 2016 HRC Celebrating Research Excellence Award and the 2014 University of Auckland Early Career Research Excellence Award, while also being a winner of the Spark Entrepreneurship Ideas Challenges in 2012 and 2014.
Director-at-Large, Twan Lammers (3-year term through 2021)
Twan Lammers, DSc, PhD
RWTH Aachen University
Professor of Medicine
Twan obtained a D.Sc. degree in radiation oncology from Heidelberg University in 2008 and a Ph.D. degree in pharmaceutics from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at the Institute for Experimental Molecular Imaging at RWTH Aachen University. He is also affiliated with the Universities of Twente and Utrecht in The Netherlands. He has published over 150 research articles and reviews and received awards, including the CRS Young Investigator Award.
Director-at-Large, Steven Little (3-year term through 2021)
Steven Little, PhD
University of Pittsburgh
William Kepler Whiteford Endowed Professor of Chemical Engineering, Bioengineering,Pharmaceutical Sciences, Immunology, Ophthalmology
The McGowan Institute for Regenerative Medicine
Steve has served as the 12th Chairman of the Department of Chemical Engineering since 2012. Dr. Little is a Co-Founder of Qrono Inc. (a biomedical startup focused on controlled release-based cancer treatments) and OTERO Inc. (a biomedical startup focused on ocular drug delivery). His work has been highlighted in a wide range of journals including Journal of Controlled Release, Journal of the American Chemical Society, Angewandte Chemie, Proceedings of the National Academy of Sciences, ACS Nano, Advanced Materials, Biomaterials and Nature Methods. He has received a number of honors for his research. Steve currently serves as the Representative for CRS Focus Groups.